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http://dxObjectives: CXCR4/CXCL12 interactions promote non–small cell lung cancer (NSCLC) growth and dissem-
ination. Furthermore, this axis might promote NSCLC resistance to chemotherapy and/or radiotherapy. There-
fore, the CXCR4/CXCL12 axis constitutes an attractive therapeutic target for the treatment of NSCLC. We
aimed to characterize the therapeutic efficacy of the novel CXCR4 antagonist BKT140 against human NSCLC.
Methods:We determined the CXCR4 expression in 5 NSCLC cell lines (H358, A549, H460, H1299, and L4).
We then tested the colony-forming capacity and proliferation of these cells in the presence of CXCL12 and
BKT140. Next, we measured the in vivo growth of A549 and H460 xenografts with or without BKT140 treat-
ment. Finally, we examined, in vitro, the potential antiproliferative effect of BKT140 combined with cisplatin or
paclitaxel and after irradiation of NSCLC cells.
Results:All tested cell lines expressed CXCR4 and showed increased colony formation in response to CXCL12
stimulation. BKT140 reduced the colony-forming capacity of NSCLC cells. Proliferation assays demonstrated
both cytotoxic and cytostatic properties for this peptide. H460 cells were the most sensitive to BKT140 and A549
cells the least. Subcutaneous administration of BKT140 significantly delayed the development of H460 xeno-
grafts and showed a similar trend for A549 xenografts. Finally, the antiproliferative effects of BKT140 appears
to be additive to those of chemotherapeutic drugs and radiotherapy.
Conclusions: Targeting the CXCL12/CXCR4 axis with BKT140 attenuated NSCLC cells tumor growth and
augmented the effects of chemotherapy and radiotherapy. Future research will benefit from delineating the
downstream mechanism of BKT140 action and defining BKT140 susceptibility markers. (J Thorac Cardiovasc
Surg 2012;144:1167-75)E
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Despite advances in surgery, chemotherapy, and radiother-
apy during the past decades, the death rate from lung cancer
remains a global health problem.1 It was estimated thatmore
than 220,000 new cases of lung cancer would be diagnosed
in the United States in 2010. Lung cancer-related mortality
was anticipated to peak at more than 150,000 cases/y, and
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The Journal of Thoracic and Car15%.2 Thus, new treatment strategies for lung cancer
patients are urgently needed. One attractive strategy to fol-
low is targeting the chemokine receptor CXCR4.3
CXCR4 is a key driver of solid malignant propagation, in
general, and of non–small cell lung cancer (NSCLC), in par-
ticular.4,5 Two lines of evidence support this claim. The first
comes from retrospective studies of human metastatic
cancers, in which high CXCR4 expression levels were
associated with a worse prognosis. The second comes
from animal experimental models demonstrating an
aggressive phenotype for high CXCR4-expressing tumor
cells, suggesting that blockage of the CXCR4/CXCL12
axis inhibits metastasis and enhances survival.4,6-8
Clinical observational studies have demonstrated that high
CXCR4 expression in NSCLC tumors was associated with
greater tumor dimensions (higher T score) and an
increased risk of disease recurrence (reduced disease-free
interval).9-11 Furthermore, in vivo experimental models
have demonstrated that blocking CXCR4 reduced
NSCLC’s metastatic potential.12 In addition, recent re-
search has suggested that CXCR4/CXCL12 interactions
in the NSCLC tumor microenvironment might act in auto-
crine and paracrine manners to enhance primary tumor
growth and could also contribute to lung cancer immune
evasion by inducing the recruitment/retention of CXCR4þdiovascular Surgery c Volume 144, Number 5 1167
Abbreviations and Acronyms
FCS ¼ fetal calf serum
NSCLC ¼ non–small cell lung cancer
RPMI ¼ Roswell Park Memorial Institute
Evolving Technology/Basic Science Fahham et al
E
T
/B
SFoxP3þ cells into the tumor microenvironment.13-15
Additional studies have suggested that expression and
activation of CXCR4 in lung cancer cells and stem cells is
associated with an increase of resistance to both
chemotherapeutic drugs and radiotherapy.16,17 Taken
together, these data advocate that targeting CXCR4 might
alter various key pathologic processes involved in NSCLC
disease propagation.
In the present study, we focused our attention on
BKT140, a novel, small peptide with CXCR4-antagonistic
properties.18 BKT140 was initially developed as an antihu-
man immunodeficiency virus agent, chemically structured
to block the entry of the CXCR4 tropic human immunode-
ficiency virus into CXCR4-expressing T cells.19,20 The
affinity of BKT140 for CXCR4 was tested using iodine-
125 radiolabeled CXCL12, a specific anti-CXCR4 anti-
body, and human immunodeficiency virus infection assays.
All 3 methods indicated high affinity of BKT140 for
CXCR4, and a one half maximal inhibitory concentration
of 1 to 5 nM was determined.19-22 Moreover, functional
assays have demonstrated that BKT140 treatment blocks
CXCL12-induced Ca2þ mobilization and inhibits
CXCL12-induced Jurkat T cell migration in similar one
half maximal inhibitory concentrations.19-22 Taken
together, these findings demonstrate that BKT140 blocks
the binding of CXCL12 to extracellular domains of
CXCR4 and inhibits CXCR4 signaling. BKT140 also
decreases autonomous CXCR4 signaling in CXCR4 wild-
type or constitutively active CXCR4 mutants, thus charac-
terizing BKT140 as an inverse CXCR4 agonist.3 Similar
to other CXCR4/CXCL12 axis-modifying drugs, such as
AMD3100 (Mozobil), BKT140 has been shown to be a pow-
erful inducer of hematopoietic stem cell mobilization.18
However, a recent report indicated that BKT140, but not
AMD3100, showed a CXCR4-dependent cytotoxic effect
toward malignant cells of hematopoietic origin.23 This sug-
gests that BKT140 could potentially target solid malignan-
cies, but this potential has yet to be defined.
In the present study, we aimed to characterize the in vitro
and in vivo therapeutic efficacy of BKT140 against human
NSCLC. Using 5 CXCR4-expressing NSCLC cell lines
(H358, A549, H460, H1299, and L4), we have demon-
strated that BKT140 has both cytostatic and cytotoxic ef-
fects on these cells. Furthermore, systemic administration
of BKT140 significantly delayed the development of
H460-derived tumors and showed a similar trend for
A549-derived tumors. Finally, we found that the1168 The Journal of Thoracic and Cardiovascular Surantiproliferative effects of BKT140 appear to be additive
to those of common chemotherapeutic drugs and
radiotherapy.
METHODS
Cell Lines
The H460 (large cell carcinoma), A549 (adenocarcinoma), H358 (bron-
choalveolar carcinoma), H1299 (large cell carcinoma) cell lines were all
purchased from American Type Culture Collection (Manassas, Va) and
maintained in Roswell Park Memorial Institute (RPMI) medium (Gibco
Laboratories, Grand Island, NY) containing 10% fetal calf serum (FCS),
1 mM Lglutamine, 100 U/mL penicillin, and 0.01 mg/mL streptomycin
(Biological Industries, Kibbutz Beth Haemek, Israel). L4 is a primary
NSCLC cell line we generated from a large cell carcinoma.15 All cell lines
were tested for mycoplasma contamination and were negative.
In Vivo Experiments
We injected 1 3 106 H460 cells mixed in 100 mL RPMI 1640 and
100 mL matrigel (BD Biosciences, San Diego, Calif) subcutaneously into
the right flank of nude mice. Tumor growth was monitored for 19 days.
Also, 13 106 A549 cells mixed in 100 mLRPMI 1640 and 100 mLmatrigel
(BD Biosciences) were injected subcutaneously into the right flank of nude
mice. Tumor growth was monitored for 35 days. Systemic BKT140 admin-
istration was performed as follows: BKT140 (400 mg/mouse dissolved in
phosphate-buffered saline) was administered once daily 6 or 7 d/wk by sub-
cutaneous injection into the left flank at a point at least 1.5 cm distant from
the right-sided tumor. The daily BKT140 injections were initiated on the
third day after tumor cell implantation. The tumor size was calculated
by measuring the tumor length and width using the following formula:
4/3 3 p 3 (length/2) 3 (width/2)2.
The animal care and use committee at Hadassah University Hospital ap-
proved the experimental protocol used in our study.
Giemsa Stain
A total of 13 105 cells/mL were cultured in flat-bottom, 24-well plates
(Corning, Corning, NY) with 1000 mL RPMI 1640 medium supplemented
with 10% FCS at 37C with 5% carbon dioxide. Next, 24 hours later, the
medium was changed to RPMI 1640 supplemented with 1% FCS with or
without 100 mg/mLBKT140. At the indicated points, the cells were fixed in
100% methanol for 30 minutes, washed in phosphate-buffered saline, and
stained with 1:20 modified Giemsa stain (Sigma-Aldrich, St. Louis, Mo)
for 20 minutes. The cells were then rinsed with tap water and images
acquired.
Colony Assays
An agar base layer was prepared as follows: 45 mL RPMI plus 12%
FCS was mixed with 15 mL RPMI 32 plus 12% FCS and 15 mL 2.5%
agar in double-distilled water. The tumor cells were suspended in RPMI
plus 10% FCS. Cell suspension was mixed in a ratio of 1:3 with the agar
base solution. This mixture was then plated on top of a preformed solid
agar base. CXCL12, at concentrations of 25, 50, 100, and 250 ng/mL,
with or without 100 mg/mL of BKT140, was added to the mixture. Fourteen
days later, the number of colonies was counted in 10 different fields.
Immunohistochemistry
Tissue sections from the tumor-bearing nude mice were routinely fixed
with formalin and embedded in paraffin. Antigen retrieval was performed,
and the sections were stained with the monoclonal anti-CXCR4 antibody
clone 12G5 (R&D Systems, Minneapolis, Minn) (1:100) using a standard
indirect avidin-biotin horseradish peroxidasemethod according to theman-
ufacturer’s instructions. 3-Amino-9-ethylcarbazole was used for color
development, and sections were counterstained with hematoxylin.gery c November 2012
FIGURE 1. A, CXCR4 expression in non–small cell lung cancer cell lines. Representative flow cytometry analyses of CXCR4 staining in H460, A549,
H358, H1299, and L4 cells shown. Control antibody (Ab) shown in purple and anti-CXCR4 antibody in green. B, Colony formation by non–small cell
lung cancer cell lines in presence of CXCL12 and BKT140. Colony formation by H460, A549, H358, H1299, and L4 cells in response to increasing
concentrations of CXCL12 (blue) or increasing concentrations of CXCL12 combined with100 mg/mL BKT140 (red) shown.
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(phosphate-buffered saline) or an isotype-matched control antibody.
Proliferation Assay
To measure cell proliferation, 4000 cells were seeded into 96-well cell
culture plates with 200 mL RPMI 1640 medium supplemented with 10%
FCS at 37C, with 5% carbon dioxide. Twenty-four hours later, the me-
dium was changed to RPMI 1640 supplemented with 1% FCS. Next, 20,
50, or 100 mg/mL BKT140, with or without cisplatin 0.1 mg/mL or pacli-
taxel 1 ng/mL or 0.1 ng/mL) was added to the medium. For the radiation
experiments, before cell plating, the cells were irradiated at 500 to 2000
cGy. Cultured cells were fixed with 2.5% glutaraldehyde at the indicated
points and stained with 1%methylene blue. Color extraction was done us-
ing 0.1 N HCl. Absorbance of the solution in each well at 570 nm was read
using a microplate reader (Anthos HTII; Biochrom Anthos, United King-
dom); 6 wells were determined for each measurement point.
Flow Cytometry
Logarithmically growing cells were harvested and washed, and 13 105
cells were stained with antihuman CXCR4 polyclonal anti-N-terminus an-
tibody (EMDMillipore, Billerica, Mass) for 30 minutes at 4C. PE-labeled
donkey antirabbit IgG (eBioscience, San Diego, Calif) was used as a sec-
ondary antibody. The incubation time was 30 minutes at 4C. The cells
were then read and analyzed using a flow cytometry activated cell sorter
(Becton Dickinson Immunocytometry Systems; BD Biosciences,The Journal of Thoracic and CarMountain View, Calif) and CellQuest software. Control staining was ob-
tained by adding IgG control or only the secondary antibody to the cells.
Survival Assay
A total of 13 105 cells/mL were cultured in flat-bottom, 24-well plates
(Corning) with 1000 mLRPMI 1640medium supplemented with 10% FCS
at 37C and 5% carbon dioxide. Twenty-four hours later, the medium was
changed to RPMI 1640 supplemented with either 1% FCS, with or without
20 mg/mL or 100 mg/mL BKT140. At the indicated points, the cells were
harvested, washed, and stained with propidium iodide solution. The num-
ber of live cells was counted and analyzed using a flow cytometry activated
cell sorter (Becton Dickinson Immunocytometry Systems) and CellQuest
software.
Statistical Analysis
The data are expressed as the mean  standard error and as absolute
values. Continuous data with a normal distribution were analyzed using
a t-test. Categorical datawere analyzed using theMann-WhitneyU test. Sta-
tistical analyses were performed using SPSS software (IBM, Somers, NY).
RESULTS
CXCL12 Induced NSCLC Colony Formation in
CXCR4-Dependent Manner
We first characterized the expression of CXCR4 in 5
NSCLC cell lines (H358, A549, H460, H1299, and L4).diovascular Surgery c Volume 144, Number 5 1169
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next tested the potential of CXCL12 to induce colony for-
mation by these cells. CXCL12 induced a dose-dependent
increase in colony formation in all tested cell lines
(Figure 1, B). The H460 cell line was most sensitive to
CXCL12 stimulation, with a 2.5-fold increase in the num-
ber of colonies formed in response to 250 ng/mL
CXCL12. The A549 cell line was the least sensitive, with
only a 1.4-fold increase in response to similar CXCL12 con-
centrations. The addition of BKT140 reduced colony for-
mation in all tested cell lines. This observation was
evident for the entire range of CXCL12 concentrations.
The inhibitory effect of BKT140 on colony formation was
most evident in the H460 and H1299 cell lines and least ev-
ident in the A549 and H358 cell lines.
BKT140 Inhibits NSCLC Proliferation
The inhibitory effect of BKT140 on colony formation by
NSCLC cell lines prompted us to study its potential antipro-
liferative effects further. Thus, we determined NSCLC pro-
liferation and survival in the presence or absence of
increasing concentrations of BKT140. BKT140 treatment
inhibited NSCLC proliferation and reduced tumor cell sur-
vival in a dose-dependent manner (Figure 2, A). The H460
cell line was most sensitive to BKT140 treatment and the
A549 cell line was the least. Treatment with low concentra-
tions of BKT140 (20 mg/mL) was sufficient to completely
arrest H460 tumor cell proliferation, and treatment with
high concentrations of BKT140 (100 mg/mL) resulted in tu-
mor cell death. In contrast, treatment with low concentra-
tions of BKT140 (20 mg/mL) did not affect A549 tumor
cell proliferation. Nevertheless, treatment with high con-
centrations of BKT140 (100 mg/mL) significantly reduced
A549 tumor cell proliferation and also had some cytotoxic
effects. The cytostatic and cytotoxic effects of the low and
high concentrations of BKT140 on the H460 and A549
cell lines are also shown in the representative Giemsa-
stained slides presented in Figure 2, B.
BKT140 Treatment Delayed NSCLC Tumor Growth
In Vivo
Once we established the in vitro antiproliferative effects
of BKT140, we sought to further confirm these observations
in vivo. We based our experimental approach on previous
publications describing the systemic effects and kinetics
of subcutaneous injection of BKT140.24,25 As a method to
test whether BKT140 injected subcutaneously at a distant
site would reach the tumor site, we stained sections of
H460 tumors from mice that were untreated or treated
with BKT140 for CXCR4. Representative staining of
tumor tissue with the control antibody or anti-CXCR4 anti-
body is shown in Figure 3, A and B, respectively. High
CXCR4 expression by the tumor cells is evident. Tumor tis-
sue sections prepared from mice treated with BKT140 did1170 The Journal of Thoracic and Cardiovascular Surnot stain for CXCR4 (Figure 3, C). To confirm that this
observation had not resulted from transcriptional downre-
gulation of CXCR4 mRNA in the BKT140-treated mice,
we performed quantitative real-time polymerase chain reac-
tion for CXCR4 mRNA on both BKT140-treated and
-untreated H460-derived tumor tissue samples. We found
no effect for BKT140 treatment on CXCR4 mRNA expres-
sion levels (Figure E1). Next, we examined the effects of
BKT140 treatment on NSCLC tumor development. We
focused on the cell lines most sensitive (H460) and least
sensitive (A549) to BKT140. BKT140 treatment signifi-
cantly reduced the volume of H460-derived tumors and
showed a similar trend for A549-derived tumors
(Figure 3, D and E). The median tumor volume was de-
creased by nearly 50% in both cell lines tested (Figure 3,
D and E).
Combining BKT140 With Chemotherapeutic Drugs
or Radiation Enhanced Inhibition Efficacy of NSCLC
Proliferation
Current treatment protocols for advanced NSCLC in-
volve concomitant or staged administration of chemothera-
peutic agents with radiotherapy.26 Among the most widely
used chemotherapeutic drugs are cisplatin and paclitaxel.
Despite the high initial response rates, the disease often re-
curs. This has been attributed in part to the increase in che-
motherapy and radiation resistance by tumor cells.26
Interference with the CXCR4/CXCL12 axis has recently
been proposed as a potential strategy to increase tumor sen-
sitivity to chemotherapeutic agents and radiotherapy.7,27
Thus, we tested the potential of BKT140 to enhance the
cytostatic and cytotoxic effects of cisplatin, paclitaxel,
and radiotherapy in the H460 and A549 cell lines. We
first tested the proliferation of H460 and A549 cell lines
after escalating radiation doses (Figure 4, A) and in the pres-
ence of increasing concentrations of cisplatin (Figure 4, B)
and paclitaxel (data not shown). From these experiments,
we defined for each treatment a dose or concentration that
showed moderate antiproliferative effects but did not com-
pletely inhibit tumor cell proliferation. For radiation pre-
treatment, the defined dose was 500 cGy (Figure 4, A).
For cisplatin, the concentration was 0.1 mg/mL (Figure 4,
B), and for paclitaxel, the concentration was 1 ng/mL or
0.1 ng/mL (data not shown). Next, we tested H460 and
A549 tumor cell proliferation in the presence of increasing
concentrations of BKT140 with or without radiation
(Figure 5, A), cisplatin (Figure 5, B) or paclitaxel (data
not shown) pretreatment. Overall, an additive antiprolifera-
tive effect for BKT140 in conjunction with these treatment
protocols was evident (Figure 5, A and B).
DISCUSSION
It is well established that CXCL12 induces stimulation of
CXCR4, as well as CXCR4 autosignaling enhances tumorgery c November 2012
FIGURE 2. A, Proliferation of non–small cell lung cancer cell lines in presence of BKT140. Proliferation of H460, A549, H358, H1299, and L4 cells in
control medium (blue), medium supplemented with 20 mg/mL (red), or medium supplemented with 100 mg/mL (green) of BKT140 shown. Indicated points
were 4, 24, and 48 hours after cell seeding. B, Representative Giemsa staining of H460 and A549 cells growing in control medium or control medium
supplemented with 20 mg/mL or 100 mg/mL of BKT140 for 48 hours.
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NSCLC cell lines, we demonstrated that CXCL12 induces
NSCLC colony formation in a dose-dependent manner.The Journal of Thoracic and CarLess clear, however, is whether altering or inhibiting
CXCR4 signaling would lead to cell cycle arrest or cell
death. To address this,we first demonstrated that the additiondiovascular Surgery c Volume 144, Number 5 1171
FIGURE 3. Representative staining of H460-derived xenografts for CXCR4. A, Staining with control antibody shown. B, Staining with anti-CXCR4 an-
tibody shown. C, Staining with anti-CXCR4 antibody of xenograft derived from mice receiving daily BKT140 treatment shown. Growth of (D) H460- and
(E) A549-derived xenografts with or without daily BKT140 treatment. Tumor volume in mice injected with, Left, H460 cells or, Right, A549 cells shown.
Blue crosses indicate control mice (no BKT140 treatment); red crosses indicate mice that received daily BKT140 injections.
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induced colony formation. We also found that the BKT140
reduced the number of colonies forming in the absence of
CXCL12 in 3 of the 5 tested cell lines (H460, H1299, and
L4). This led us to examine whether BKT140 would delay
spontaneous NSCLC tumor cell proliferation in the absence
of CXCL12. In line with this prediction, we found that
BKT140 had both cytostatic and cytotoxic effects on all
tested cell lines. The H460 cell line was most sensitive to
BKT140 and the A549 cell line was the least. Focusing on
these cell lines, we demonstrated that a single daily dose
of BKT140 was sufficient to induce delayed propagation
of H460-derived tumors and, to a lesser extent, of A549-
derived tumors. Overall, these data have established for
the first time the antiproliferative effects of BKT140 against
human NSCLC cell lines and tumor xenografts.
Our findings have also demonstrated an enhanced anti-
proliferative profile for cisplatin and irradiation pretreat-
ment when introduced in conjunction with BKT140. This
is of particular importance, because drugs that increase
the chemosensitivity and radiosensitivity of malignant cells
are continuously being developed to improve the therapeu-
tic outcomes and facilitate reduced dose administration.26
The mechanism by which BKT140 adds to the effect of
chemotherapeutic drugs and radiotherapy has yet to be1172 The Journal of Thoracic and Cardiovascular Surelucidated and confirmed in vivo. One intriguing possibility
to follow is whether BKT140 specifically targets lung can-
cer initiating cells (lung cancer stem cells). These cells rep-
resent a small subpopulation of tumor cells characterized by
high self-renewal capacity, enhanced colony-forming ca-
pacity, and superior tumor-forming capacity.28 Such cells,
which have been identified in both human NSCLC tumors
and NSCLC cell lines, are considered unique owing to their
resistance to chemotherapeutic drugs and radiotherapy.29-31
Preliminary support for the potential role of BKT140 in
targeting lung cancer-initiating cells comes from a recent
report that has demonstrated that upregulation of CXCR4
is functionally crucial for maintenance of stemness proper-
ties in drug-resistant NSCLC cells.16,17
Worth mentioning are observations indicating that
the vast majority of solid malignant tumors express
CXCR4 and that various oncogenic alternations, such
as rearranged in transformation/papillary thyroid carci-
noma rearrangement, VHL mutation, and TP53 muta-
tion, result in CXCR4 upregulation.4 Furthermore, tumor
microenvironment-dependent conditions such as hypoxia
also specifically induce the upregulation of CXCR4 and
CXCL12.4 Hence, it is tempting to speculate that the
inhibitory effects of BKT140 against NSCLC might also
be applicable to other solid malignancies. Our preliminarygery c November 2012
FIGURE 4. Proliferation of H460 and A549 cells with increasing concentration of cisplatin or increasing radiation doses. Days 0, 1, 3, and 6 shown.
Fahham et al Evolving Technology/Basic Scienceunpublished data have suggested that certain non-NSCLC
malignant cell lines are also susceptible to BKT140.
More broadly, CXCR4 is considered a valid target for
novel anticancer therapies, and more than 15 new drugs
that target the CXCR4/CXCL12 axis are beingFIGURE 5. Proliferation of H460 and A549 cells in presence of cisplatin 0.1 mg
of BKT140. Days 0, 1, 3, and 6 shown.
The Journal of Thoracic and Cardeveloped.3,18 Several of these drugs, including BKT140,
have entered the phase of clinical trial development.3,18
Nevertheless, the potential role of CXCR4 antagonists in
targeting of NSCLC remains mostly unknown. The sole
Food and Drug Administration–approved anti-CXCR4/mL or after irradiation (500 cGy)with or without increasing concentrations
diovascular Surgery c Volume 144, Number 5 1173
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liferation of a subpopulation of drug-resistant A549
cells.17,32 Our work has contributed to the field by
demonstrating for the first time the in vitro and in vivo
inhibitory effects of BKT140 against a wide range of
NSCLC cell lines, representing diverse NSCLC
pathologic subtypes, including adenocarcinoma, large cell
carcinoma, and bronchioalveolar carcinoma. Squamous
cell carcinoma cell lines were not included in the present
study, and their susceptibility to BKT140 should be
determined in future research. Also, although all tested
cell lines expressed CXCR4, they showed a diverse
response to BKT140-induced toxicity. Potential explana-
tions for this diverse effect include differential prosur-
vival/proliferation dependence on CXCR4 signaling
among the various cell lines and a lack of absolute specific-
ity of BKT140 for CXCR4, allowing other receptors, such
as CXCR7, which is also known to bind CXCL12, to bind
BKT140 and modulate its effects. This highlights the neces-
sity in future research to better define BKT140 susceptibil-
ity markers. Finally, taking into consideration the
importance of the CXCR4/CXCL12 axis in mediating tu-
mor microenvironment interactions, future research will
benefit from focusing on the mechanisms by which
CXCR4 antagonists such as AMD3100 and BKT140 regu-
late tumor stroma and tumor immune cell cross-talk.
CONCLUSIONS
Our findings have indicated that targeting the CXCL12/
CXCR4 axis with BKT140 significantly attenuates NSCLC
tumor growth and might augment the effects of antitumor
chemotherapy and radiotherapy. These promising results
suggest that future research will benefit from delineating
the downstream mechanisms of BKT140 action and better
defining BKT140 cell susceptibility markers. We believe
that by following these paths, scientists and physicians
will advance the introduction of CXCR4-based therapeutics
for NSCLC, in particular, and solid malignancies, in
general.
The authors would like to thank Ishai and Erela Kedem, Reho-
vot, Israel, and Tomi Nadashi, Haifa, Israel, for their generous sup-
port of this research.
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Dr Chadrick Denlinger (Charleston, SC). Dr Wald, I enjoyed
your presentation. This work represents yet another contribution
from you and your laboratory related to the chemokines and che-
mokine receptors in the development and progression of cancer.
The importance of BKT140 and other similar drugs will likely
continue to grow as these drugs approach the clinical realm.
Your presentation this morning also demonstrates the systemic ef-
ficacy of BKT140 in your xenograft studies.
Your presentation focused primarily on the specificity of
BKT140 as it affects the CXCR4 receptor. As 1 of your earlier
slides demonstrated, there are a number of different chemokine re-
ceptors that likely have multiple layers of redundancy related to
similar ligand binding but different receptors and overlapping in-
tracellular second messenger systems. In this study, you focused
exclusively on the small molecule inhibitors of CXCR4—did
you consider also using more specific molecular agents, such as
short hairpin loops or siRNAs, as a more specific target for the
CXCR4?
Dr Wald. I think that this is an important concern. Actually,
siRNA silencing is indeed a great option to demonstrate the spec-
ificity. We have had some trouble achieving good transfectants and
good silencing of CXCR4 with our cell lines. However, it is known
that BKT140 competes with the antibody we used in immunohis-
tochemistry assay for a binding site on the CXCR4 receptor. This
is the anti-CXCR4 12G5 clone. Therefore, I believe that we can
exclude downregulation of the BKT140. Furthermore, there has
been extensive work done with the molecule showing its specific-
ity for CXCR4; nonetheless, we cannot absolutely rule out other
possibilities, and, indeed, it is possible that some of the effectsThe Journal of Thoracic and Carof BKT140 might be related to other mechanisms, rather than
blocking of CXCR4.
Dr Denlinger. Similarly, all the cell lines used in the study ex-
pressed CXCR4. Have you found some NSCLC cell lines that do
not express CXCR4 that could be possibly used as negative con-
trols for similar studies?
DrWald. The lines we have screened have all had some expres-
sion of CXCR4. Furthermore, we observed that when implanted in
mice, many cells that do not express CXCR4 tend to upregulate the
receptor and express it in vivo.
Dr Denlinger. In previous work from your group, you indicated
that it is primarily the fibroblasts that release the CXCL12 that
bind to the CXCR4 receptor. In some of the studies presented to-
day, no fibroblasts were involved, yet BKT140 seemed to have
antiproliferative effects. How do you explain these results?
Dr Wald.Most of these cell lines used in our experiments also
express CXCL12 in vitro, so an autocrine loop is possible.
Another issue that I think is important to consider is that the
mechanism by which the drug acts in vitro and in vivo might not
be similar. It is reasonable to assume that when cells are trans-
planted in vivo, CXCR12 and CXCR4 probably regulate multiple
processes in the tumor microenvironment. Therefore, I am not cer-
tain whether the effect we see in vivo simply represents the inhib-
itory effect or the cytotoxic effect of the drug ex vivo. Furthermore,
I am not certain that all the cytotoxic effects of the drug in vitro are
absolutely dependent on blocking the autocrine loop. I believe that
this is the casewhen performing colony assay. In these assays, it has
been also shown that other CXCR4 inhibitors, such as AMD300,
can block colony formation. However, proliferation is only blocked
by BKT140, not by other small molecules that target CXCR4.diovascular Surgery c Volume 144, Number 5 1175
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FIGUREE1. Quantitative real-time polymerase chain reaction for CXCR4mRNA performed on both BKT140-treated and -untreated H460-derived tumor
tissue samples and cultured H460 cells. Log(10) of CXCR4 mRNA expression levels in each sample shown. No significant difference were seen in CXCR4
mRNA levels among BKT140-treated and -untreated tumors. T1, H460 tumor after BKT140; T2, H460 tumor after BKT140; T3, H460 tumor control; T4,
H460 tumor control; C, H460 cell line in vitro.
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